Form 4: Ligand Pharmaceuticals Executive Sells Shares
Insider Transaction (Form 4)
Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals Inc, sold 5,000 shares of common stock on August 3, 2026.
Summary
- Option exercise/conversion: acquired 5,000 Common Stock at $52.27 ($261,350) on August 3, 2026; holds 46,514 after (Direct).
- Open-market sale: disposed of 105 Common Stock at $284.14 ($29,834) on August 3, 2026; holds 46,409 after (Direct).
- Open-market sale: disposed of 33 Common Stock at $284.55 ($9,390) on August 3, 2026; holds 46,376 after (Direct).
- Open-market sale: disposed of 157 Common Stock at $285.74 ($44,860) on August 3, 2026; holds 46,219 after (Direct).
- Open-market sale: disposed of 1,032 Common Stock at $286.80 ($295,974) on August 3, 2026; holds 45,187 after (Direct).
- Open-market sale: disposed of 1,214 Common Stock at $287.77 ($349,357) on August 3, 2026; holds 43,973 after (Direct).
- Open-market sale: disposed of 356 Common Stock at $288.75 ($102,795) on August 3, 2026; holds 43,617 after (Direct).
- Open-market sale: disposed of 503 Common Stock at $289.80 ($145,771) on August 3, 2026; holds 43,114 after (Direct).
- Open-market sale: disposed of 200 Common Stock at $290.60 ($58,120) on August 3, 2026; holds 42,914 after (Direct).
- Open-market sale: disposed of 991 Common Stock at $291.71 ($289,086) on August 3, 2026; holds 41,923 after (Direct).
- Open-market sale: disposed of 409 Common Stock at $292.82 ($119,763) on August 3, 2026; holds 41,514 after (Direct).
- Option exercise/conversion: disposed of 5,000 Employee Stock Option (right to buy) on August 3, 2026; holds 29,444 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,444,951 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Andrew Reardon — Officer (CLO & Secretary)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-03 | Option exercise/conversion | Common Stock | 5,000 | $52 | $261.4K | 46,514 |
| 2026-08-03 | Open-market sale | Common Stock | 105 | $284 | $29.8K | 46,409 |
| 2026-08-03 | Open-market sale | Common Stock | 33 | $285 | $9.4K | 46,376 |
| 2026-08-03 | Open-market sale | Common Stock | 157 | $286 | $44.9K | 46,219 |
| 2026-08-03 | Open-market sale | Common Stock | 1,032 | $287 | $296.0K | 45,187 |
| 2026-08-03 | Open-market sale | Common Stock | 1,214 | $288 | $349.4K | 43,973 |
| 2026-08-03 | Open-market sale | Common Stock | 356 | $289 | $102.8K | 43,617 |
| 2026-08-03 | Open-market sale | Common Stock | 503 | $290 | $145.8K | 43,114 |
| 2026-08-03 | Open-market sale | Common Stock | 200 | $291 | $58.1K | 42,914 |
| 2026-08-03 | Open-market sale | Common Stock | 991 | $292 | $289.1K | 41,923 |
| 2026-08-03 | Open-market sale | Common Stock | 409 | $293 | $119.8K | 41,514 |
| 2026-08-03 | Option exercise/conversion | Employee Stock Option (right to buy) | 5,000 | — | — | 29,444 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-03 | Option exercise/conversion (5,000 shares) |
| 2026-08-03 | Open-market sale (105 shares) |
| 2026-08-03 | Open-market sale (33 shares) |
| 2026-08-03 | Open-market sale (157 shares) |
| 2026-08-03 | Open-market sale (1,032 shares) |
| 2026-08-03 | Open-market sale (1,214 shares) |
| 2026-08-03 | Open-market sale (356 shares) |
| 2026-08-03 | Open-market sale (503 shares) |
| 2026-08-03 | Open-market sale (200 shares) |
| 2026-08-03 | Open-market sale (991 shares) |
| 2026-08-03 | Open-market sale (409 shares) |
| 2026-08-03 | Option exercise/conversion (5,000 shares) |
Keywords
insider transaction, Form 4, LGND, LIGAND PHARMACEUTICALS INC, bearish, Andrew Reardon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.